San Diego, CA 7/30/18—Omniome has completed a Series B financing raising $60 million in new funding. The company's Sequencing By Binding technology promises greater precision of nucleotide and DNA matching. "We have been able to validate the tremendous power of our proprietary sequencing biochemistry. Now we are directing our efforts on product development to rapidly advance our first commercial instrument prototypes," stated Omniome President and CEO Dave Mullarkey. "We appreciate the continued support from our current investors and welcome new investors Decheng Capital, Hillhouse Capital, Lam Research Capital and Nan Fung Life Sciences." The label-free sequencing technology utilizes plasmonic nanohole arrays and imaging detection. Founded in 2013, the company has 40 employees, according to its website.